What is BPC-157? A Complete Research Guide.

Reviews of the preclinical literature describe several overlapping pathways. BPC-157 appears to activate VEGFR2 and nitric-oxide synthesis via the Akt-eNOS axis, promoting angiogenesis — the formation of new blood vessels — alongside fibroblast activity. It also engages ERK1/2 signalling, which is involved in cell growth and repair.[4]

Angiogenesis matters most in poorly vascularised tissue. Tendons and ligaments heal slowly precisely because their blood supply is limited, so a compound that promotes vessel growth in these tissues is of genuine research interest. Wound-healing studies report increased collagen deposition and reepithelialisation in animal models.[5]

These mechanisms are inferred from animal and cell studies. Which of them would matter in humans, at what exposure, and with what effect size, cannot be answered from the existing literature.

The 2019 Cell and Tissue Research review found consistently positive healing effects across tendon, ligament, and muscle injury models — but emphasised that efficacy is yet to be confirmed in humans, and that only a handful of research groups have studied the peptide in depth over two decades.[2]

A 2025 systematic review in HSS Journal, written from an orthopaedic sports-medicine perspective, synthesised the literature from database inception to June 2024. It found preclinical potential for fractures, tendon ruptures, ligament tears, and muscle injuries — while noting that BPC-157 lacks FDA approval and is banned in professional sport.[3]

A 2025 narrative review in Current Reviews in Musculoskeletal Medicine counted only three pilot studies in humans — covering intraarticular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics. No adverse effects were reported in those small studies, but the authors stress that rigorous, large-scale trials are lacking.[4]

Animal studies have not identified a lethal dose (LD1 was not achieved in early ulcer and multiple sclerosis trial contexts), and the three small human pilot studies reported no adverse effects. That is reassuring but not equivalent to a safety profile established through regulated clinical trials.[4]

The HSS Journal systematic review is direct about the context: BPC-157 has no FDA approval, is prohibited in professional sport, and its increasing clinician and athlete use runs ahead of the evidence. Long-term human safety data does not exist.[3]

Promoting angiogenesis is a double-edged property in theory — the same vessel growth that could aid healing is a pathway researchers examine carefully. No evidence links BPC-157 to harm in humans, but absence of evidence in a barely-studied compound is not evidence of absence.

BPC-157 is not an approved medicine in the United States, the European Union, or other major regulatory jurisdictions, and it is on the World Anti-Doping Agency prohibited list for competitive sport. It is sold and studied as a research compound.[3]

In the UAE, the Emirates Drug Establishment maintains the public registered medical product directory. This guide does not use directory presence or absence to infer approval, legality, or permission for use; those questions require confirmation from the EDE. Afiya Labs lists BPC-157 strictly as a laboratory research reference material.[6]